What does published literature tell us about the clinical efficacy of INTERCEPT treated platelets?

Dr. Joan Cid Vidal
Hospital Clínic
Barcelona, Spain

Global Headquarters

1220 Concord Avenue

Concord, CA US 94520

+1 925.288.6000

European Headquarters

Stationsstraat 79-D

3811 MH Amersfoort, Netherlands

+31 (0) 33 49 60 600

Cookie Notice
Legal
Privacy Policy
Follow us

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2025 Cerus Corporation. Cerus. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00860 MKT-EN 00861 MKT-EN 00844 MKT-EN 00857 MKT-EN 00858 MKT-EN 00859 MKT-EN 00856 MKT-EN 00855 MKT-EN 00854 MKT-EN 00853 MKT-EN 00852 MKT-EN 00851 MKT-EN 00850 MKT-EN 00849 MKT-EN 00848 MKT-EN 00847 MKT-EN 00846 MKT-EN 00845